Remove Adverse Reactions Remove Labelling Remove Pharmacy Management
article thumbnail

FDA Approvals: September 2022 Recap

Digital Pharmacist

Common adverse reactions include conjunctival/ocular hyperemia, photophobia, blurred vision, dry eye, pain, headache, irritation, and visual impairment. . Rolvedon was supported by data from two Phase 3, randomized, open-label, non-inferiority clinical trials, ADVANCE, and RECOVER, which evaluated safety and efficacy.